Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab

OBJECTIVES: In a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State (LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb randomised controlled trial (RCT) (MUSE [NCT01438489]) and then utilize LLDAS to discriminate between anifrolumab and pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Morand, Eric F, Trasieva, Teodora, Berglind, Anna, Illei, Gabor G, Tummala, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909750/
https://www.ncbi.nlm.nih.gov/pubmed/29420200
http://dx.doi.org/10.1136/annrheumdis-2017-212504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909750/
https://www.ncbi.nlm.nih.gov/pubmed/29420200
http://dx.doi.org/10.1136/annrheumdis-2017-212504

Ejemplares similares